Sanofi (LON:0A2V)
London · Delayed Price · Currency is GBP · Price in USD 46.71
+0.49 (1.05%)
At close: Jan 30, 2026
Sanofi Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 43,626 | 41,081 | 37,817 | 37,651 | 37,761 |
Other Revenue | 3,090 | 3,205 | 3,292 | 2,653 | 1,414 |
| 46,716 | 44,286 | 41,109 | 40,304 | 39,175 | |
Revenue Growth (YoY) | 5.49% | 7.73% | 2.00% | 2.88% | 4.83% |
Cost of Revenue | 12,923 | 13,195 | 12,619 | 11,869 | 12,251 |
Gross Profit | 33,793 | 31,091 | 28,490 | 28,435 | 26,924 |
Selling, General & Admin | 9,543 | 9,247 | 9,003 | 8,785 | 9,599 |
Research & Development | 7,842 | 7,394 | 6,507 | 6,501 | 5,692 |
Amortization of Goodwill & Intangibles | 1,776 | 1,749 | 1,911 | 1,578 | 1,580 |
Other Operating Expenses | 5,162 | 3,832 | 2,948 | 1,190 | 1,488 |
Operating Expenses | 24,323 | 22,222 | 20,369 | 18,054 | 18,359 |
Operating Income | 9,470 | 8,869 | 8,121 | 10,381 | 8,565 |
Interest Expense | -563 | -641 | -589 | -402 | -362 |
Interest & Investment Income | 394 | 413 | 527 | 239 | 3 |
Earnings From Equity Investments | -155 | 60 | -136 | 55 | 39 |
Currency Exchange Gain (Loss) | - | 6 | -2 | -3 | 2 |
Other Non Operating Income (Expenses) | - | -268 | -574 | -14 | 70 |
EBT Excluding Unusual Items | 9,146 | 8,439 | 7,347 | 10,256 | 8,317 |
Merger & Restructuring Charges | -1,264 | -1,406 | -1,039 | -1,090 | -824 |
Gain (Loss) on Sale of Investments | - | - | -1 | 1 | 3 |
Gain (Loss) on Sale of Assets | 483 | 539 | 484 | 481 | 418 |
Asset Writedown | -2,241 | -248 | -896 | 203 | -192 |
Legal Settlements | - | -470 | -196 | -143 | - |
Other Unusual Items | -104 | -96 | 416 | 284 | 115 |
Pretax Income | 6,020 | 6,758 | 6,115 | 9,992 | 7,837 |
Income Tax Expense | 1,043 | 1,204 | 1,017 | 1,909 | 1,558 |
Earnings From Continuing Operations | 4,977 | 5,554 | 5,098 | 8,083 | 6,279 |
Earnings From Discontinued Operations | 2,874 | 64 | 338 | 401 | - |
Net Income to Company | 7,851 | 5,618 | 5,436 | 8,484 | 6,279 |
Minority Interest in Earnings | -38 | -58 | -36 | -113 | -56 |
Net Income | 7,813 | 5,560 | 5,400 | 8,371 | 6,223 |
Net Income to Common | 7,813 | 5,560 | 5,400 | 8,371 | 6,223 |
Net Income Growth | 40.52% | 2.96% | -35.49% | 34.52% | -49.38% |
Shares Outstanding (Basic) | 1,220 | 1,251 | 1,252 | 1,252 | 1,253 |
Shares Outstanding (Diluted) | 1,220 | 1,256 | 1,256 | 1,257 | 1,258 |
Shares Change (YoY) | -2.84% | -0.02% | -0.04% | -0.08% | -0.18% |
EPS (Basic) | 6.40 | 4.44 | 4.31 | 6.69 | 4.97 |
EPS (Diluted) | 6.40 | 4.44 | 4.31 | 6.67 | 4.95 |
EPS Growth | 44.16% | 2.94% | -35.31% | 34.73% | -49.28% |
Free Cash Flow | 8,892 | 7,348 | 8,639 | 8,997 | 9,044 |
Free Cash Flow Per Share | 7.29 | 5.85 | 6.88 | 7.16 | 7.19 |
Dividend Per Share | 4.120 | 3.920 | 3.760 | 3.560 | 3.330 |
Dividend Growth | 5.10% | 4.25% | 5.62% | 6.91% | 4.06% |
Gross Margin | 72.34% | 70.20% | 69.30% | 70.55% | 68.73% |
Operating Margin | 20.27% | 20.03% | 19.75% | 25.76% | 21.86% |
Profit Margin | 16.72% | 12.55% | 13.14% | 20.77% | 15.88% |
Free Cash Flow Margin | 19.03% | 16.59% | 21.02% | 22.32% | 23.09% |
EBITDA | 12,680 | 11,664 | 11,076 | 13,093 | 11,251 |
EBITDA Margin | 27.14% | 26.34% | 26.94% | 32.49% | 28.72% |
D&A For EBITDA | 3,210 | 2,795 | 2,955 | 2,712 | 2,686 |
EBIT | 9,470 | 8,869 | 8,121 | 10,381 | 8,565 |
EBIT Margin | 20.27% | 20.03% | 19.75% | 25.76% | 21.86% |
Effective Tax Rate | 17.33% | 17.82% | 16.63% | 19.11% | 19.88% |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.